SCHEMBL25322111

SCHEMBL25322111

C[C@H](Nc1cn[nH]c(=O)c1C(F)(F)F)/C(F)=C/Cn1ccc2cc(-c3ncc(C(F)(F)F)cn3)c(F)c(F)c2c1=O

nearest known ligand 0.45

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ TIPARP Q7Z3E1 19/20 0.45
▸ PARP1 P09874 2/20 0.38
▸ PARP14 Q460N5 2/20 0.38
▸ PARP12 Q9H0J9 2/20 0.38
▸ TNKS2 Q9H2K2 2/20 0.38
▸ PARP11 Q9NR21 2/20 0.38
▸ PARP2 Q9UGN5 2/20 0.38
▸ TNKS O95271 1/20 0.38
▸ PARP10 Q53GL7 1/20 0.38
▸ CYP2C9 P11712 1/20 0.38
▸ PARP16 Q8N5Y8 1/20 0.38
▸ PARP4 Q9UKK3 1/20 0.38
▸ PARP3 Q9Y6F1 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25322114 1.00 TIPARP (0.45) TIPARPPARP1PARP14PARP12TNKS2
SCHEMBL25322118 1.00 TIPARP (0.45) TIPARPPARP1PARP14PARP12TNKS2
SCHEMBL30550629 1.00 TIPARP (0.45) TIPARPPARP1PARP14PARP12TNKS2
SCHEMBL25323303 1.00 TIPARP (0.45) TIPARPPARP1PARP14PARP12TNKS2
SCHEMBL30550674 1.00 TIPARP (0.45) TIPARPPARP1PARP14PARP12TNKS2
SCHEMBL25320140 0.88 TIPARP (0.46) TIPARPPARP1PARP14PARP12TNKS2
SCHEMBL30550589 0.88 TIPARP (0.46) TIPARPPARP1PARP14PARP12TNKS2
SCHEMBL25320143 0.88 TIPARP (0.46) TIPARPPARP1PARP14PARP12TNKS2
SCHEMBL25320134 0.88 TIPARP (0.46) TIPARPPARP1PARP14PARP12TNKS2
SCHEMBL31362929 0.84 TIPARP (0.62) TIPARPPARP1PARP14PARP12TNKS2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12459922-B2 PARP7 inhibitors GILEAD SCIENCES, INC. (US) 2025-11-04 — — US disclosed
US-20230365529-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. 2023-11-16 — — US disclosed
US-20230365529-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. 2023-11-16 — — US disclosed
WO-2023147418-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2023-08-03 — — WO disclosed
WO-2023147418-A1 PARP7 INHIBITORS GILEAD SCIENCES, INC. (US) 2023-08-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12459922-B2 PARP7 inhibitors PARP1, PARP11, PARP2 TIPARP 491/4885PARP1 1/4885PARP14 10/4885
US-20230365529-A1 PARP7 INHIBITORS PARP1, PARP11, PARP2 TIPARP 491/4885PARP1 1/4885PARP14 10/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback